Cargando…

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The m...

Descripción completa

Detalles Bibliográficos
Autores principales: AbdElhameid, Mohammed K., Labib, Madlen B., Negmeldin, Ahmed T., Al-Shorbagy, Muhammad, Mohammed, Manal R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136361/
https://www.ncbi.nlm.nih.gov/pubmed/30191744
http://dx.doi.org/10.1080/14756366.2018.1503654
_version_ 1783354983883735040
author AbdElhameid, Mohammed K.
Labib, Madlen B.
Negmeldin, Ahmed T.
Al-Shorbagy, Muhammad
Mohammed, Manal R.
author_facet AbdElhameid, Mohammed K.
Labib, Madlen B.
Negmeldin, Ahmed T.
Al-Shorbagy, Muhammad
Mohammed, Manal R.
author_sort AbdElhameid, Mohammed K.
collection PubMed
description In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells accumulation in the sub-G1 phase, and cell cycle arrest at G2/M phase. The apoptotic inducing activities of compounds 5 and 21were correlated to the elevation of p53, increase in Bax/Bcl-2 ratio, and increase in caspase-3/7.Compounds 5 and 21 showed potent inhibition againstVEGFR-2 (IC(50) = 0.59 and 1.29 μM) and β-tubulin polymerization (73% and 86% inhibition at their IC(50) values).Molecular docking was performed with VEGFR-2 and tubulin binding sites to explain the displayed inhibitory activities.
format Online
Article
Text
id pubmed-6136361
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61363612018-09-14 Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors AbdElhameid, Mohammed K. Labib, Madlen B. Negmeldin, Ahmed T. Al-Shorbagy, Muhammad Mohammed, Manal R. J Enzyme Inhib Med Chem Article In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells accumulation in the sub-G1 phase, and cell cycle arrest at G2/M phase. The apoptotic inducing activities of compounds 5 and 21were correlated to the elevation of p53, increase in Bax/Bcl-2 ratio, and increase in caspase-3/7.Compounds 5 and 21 showed potent inhibition againstVEGFR-2 (IC(50) = 0.59 and 1.29 μM) and β-tubulin polymerization (73% and 86% inhibition at their IC(50) values).Molecular docking was performed with VEGFR-2 and tubulin binding sites to explain the displayed inhibitory activities. Taylor & Francis 2018-09-07 /pmc/articles/PMC6136361/ /pubmed/30191744 http://dx.doi.org/10.1080/14756366.2018.1503654 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
AbdElhameid, Mohammed K.
Labib, Madlen B.
Negmeldin, Ahmed T.
Al-Shorbagy, Muhammad
Mohammed, Manal R.
Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title_full Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title_fullStr Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title_full_unstemmed Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title_short Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
title_sort design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas vegfr-2inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136361/
https://www.ncbi.nlm.nih.gov/pubmed/30191744
http://dx.doi.org/10.1080/14756366.2018.1503654
work_keys_str_mv AT abdelhameidmohammedk designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors
AT labibmadlenb designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors
AT negmeldinahmedt designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors
AT alshorbagymuhammad designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors
AT mohammedmanalr designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors